• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Pharmaceutical companies and non-profits team up to provide affordable hepatitis C treatment in Latin America

Home > Press releases

Pharmaceutical companies and non-profits team up to provide affordable hepatitis C treatment in Latin America

Hepatitis C virus
Buenos Aires, Argentina / Geneva, Switzerland — 5 Mar 2018
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

A new collaboration between pharmaceutical companies and non-profit organizations will manufacture and supply a new, more affordable, hepatitis C treatment regimen in Latin America. An estimated 3.5 million people live with this viral disease in Latin America including around 325,000 in Argentina, with high treatment prices one of the many barriers to access for life-saving care.

Under the terms of the collaboration announced at the 18th International Congress on Infectious Diseases (ICID), Buenos Aires, Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) will supply the active pharmaceutical ingredients for sofosbuvir and drug candidate ravidasvir. Pharmaceutical company Insud Pharma and Argentinian research and development company Laboratorio Elea Phoenix (Elea) will register, manufacture, and distribute ravidasvir and sofosbuvir in Latin America. Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with clinical trials data and jointly with non-profit foundation Mundo Sano will collaborate on advocacy activities to boost access to easy diagnosis and affordable treatment of hepatitis C virus (HCV).

“Our ambition is to help develop a new safe, effective, and affordable treatment regimen which will allow countries to take a public health approach to hepatitis C,” said Dr Bernard Pécoul, DNDi Executive Director.

Currently a 12-week course of HCV treatment is available in Argentina for at least US$7,000, in Chile for $12,000 and in Brazil for over $6,000. Although the cost of manufacturing ravidasvir is potentially higher than some direct-acting antivirals (DAAs), the commitment from all partners to a reasonable profit margin means that the target price of the new ravidasvir/sofosbuvir combination will be under $500 in Latin America.

“We are proud to have Insud Pharma, Elea, and Pharco as reliable industrial partners capable of registering and manufacturing what will be a quality new drug that could transform the dynamic of access to HCV treatment in Latin America,” said Silvia Gold, President of Mundo Sano.

Ravidasvir is an NS5A inhibitor produced by Pharco, one of a new generation of DAAs that are revolutionizing the treatment of hepatitis C. DNDi clinical trials are testing its potential use as a treatment in combination with sofosbuvir, an existing DAA, to prove its pan genotypic profile in treatment-naïve and treatment-experienced patients, in cirrhotic and non-cirrhotic patients, in people co-infected with both HCV and HIV, and in people who inject drugs. The full safety and efficacy results of a Phase II/III clinical trial in 301 patients in Malaysia and Thailand, covering the same genotypes as are prevalent in Latin America, will be published in April 2018. In an earlier Phase III clinical trial in 300 patients in Egypt, conducted by Pharco, ravidasvir showed an overall cure rate of 98% in patients with genotype 4 when used in combination with sofosbuvir.

“We hope that our collaboration will lead to widespread access to safe, effective, and affordable treatment for patients in Argentina and around the region,” said Dr Sherine Helmy, CEO of Pharco Pharmaceuticals.

“As a leading Argentine pharmaceutical company, one of Elea’s principles is the development of new effective, safe, and affordable therapies for people. This new treatment will be fully produced in our manufacturing facilities in Argentina and will be available for all those living with this disease in Argentina and Latin America,” said Eduardo Spitzer, Scientific Director, Elea Phoenix.

Countries in the region are adopting different strategies to face the high price of HCV treatment. However, a number of patent applications that could prevent affordable access to sofosbuvir are pending in Argentina and in other Latin American countries, all of which are middle-income countries (MIC) as per the World Bank’s classification. In September 2017, Malaysia, also an MIC, issued a “government use” licence enabling access to more affordable versions of the expensive medicine. This landmark decision will help the more than 400,000 people living with hepatitis C in Malaysia access sofosbuvir, and could have important repercussions in the global effort to secure access to treatments for this viral disease.

Media contacts

  • Insud Pharma/Elea/Mundo Sano: Lorena Sueiro, lsueiro@grupoinsud.com
  • DNDi: media@dndi.org
  • Pharco: Yaser Fayed, yaserfayed@pharco.org

About Elea Phoenix

With more than 75 years of experience, Elea Phoenix researches and develops reliable medicines for a range of medicinal specialties. It is one of the top pharmaceutical companies of Argentina in terms of revenues. It has leading brands, innovative R&D projects, and licenses from major international companies. With its own production plants and a wide distribution network, it is oriented to the development of new products, mainly in the areas of Women’s Health, Cardiology, Neurosciences, Oncology and OTC drugs. www.elea.com

 

About Mundo Sano

Mundo Sano is a private foundation dedicated to developing research, prevention, diagnosis and treatment programs to reduce the impact of neglected diseases. www.mundosano.org

 

About Pharco

Pharco Pharmaceuticals, Inc. is the largest manufacturer of pharmaceuticals in Egypt, focused on research, formulation, manufacturing and commercialization of pharmaceutical products in the MENA region. Today, Pharco employs over 8,000 employees, and has over 650M product sales units—ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 47 countries around the world. Pharco works towards one goal…to provide highly effective and safe pharmaceutical products to patients at an affordable price. Pharco licensed ravidasvir hydrochloride, formerly known as (PPI-668), from Presidio Pharmaceuticals, a San Francisco-based clinical stage, specialty pharmaceutical company. www.pharco.org

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit R&D organization working to deliver new treatments for neglected patients, in particular sleeping sickness, Chagas disease, leishmaniasis, filaria, paediatric HIV/AIDS, and hepatitis C. www.dndi.org

 

Partnership Registration & access Hepatitis C

Read, watch, share

Loading...
Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

Statements
12 Apr 2022

DNDi intervention at the Intergovernmental Negotiating Body first round of public hearings

Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi
Press releases
8 Apr 2022

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License